Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma

Figure 4

Impact of CIFI on prognosis in melanoma patients with distinct clinical characteristics. (a) Male. (b) Female. (c) Age <60. (d) Age ≥60. (e) T1 + T2. (f) T3 + T4. (g) N0. (h) N1–N3. (i) Stage 1 + Stage 2. (j) Stage 3 + Stage 4.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)